Qnexa News

Qnexa News From AOL News

Contrave Rejected: What Does the FDA Have Against Diet Pills?

Today the Food and Drug Administration declined to approve Contrave, a new prescription weight-loss drug that an FDA advisory panel had recommended for approval. The FDA ruling on Contrave told drugmaker Orexigen Therapeutics that the agency was concerned about long-term use and potential implications on heart health....

FDA Panel Rejects Experimental Weight Loss Pill

GAITHERSBURG, MD. (July 15) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight. The Food and Drug Administration panel voted 10-6 against Vivus's Qnexa, citing...

Positive Qnexa Review Follows 5 Notable Diet Pill Disasters

(July 13) -- Qnexa, one of three anti-obesity drugs being reviewed by the Food and Drug Administration, effectively reduces body weight among obese patients. That's the bottom line from the FDA today, ahead of a final decision in October. But the agency remains wary of Qnexa's potential side effects: The drug has been...

Background on Qnexa

The combination of the drugs phentermine and topiramate (trade name Qnexa) is an investigational medication for the treatment of obesity and related conditions such as type 2 diabetes and has been found to lower blood pressure and cholesterol.

more at wikipedia »